- Patients with cancer have an increased risk for SARS-CoV-2 infection vs those without.
- Patients with prostate cancer receiving androgen-deprivation therapy (ADT) show lower risk for infection vs those who did not receive ADT or with any other type of cancer.
Why this matters
- These authors call for further exploration of the protective effect of ADT against COVID-19.
- Study of 4532 SARS-CoV-2-positive male patients with or without cancer.
- Funding: Supported by grant to author from European Research Council; Swiss Cancer League; Swiss National Science Foundation; Prostate Cancer Foundation; Italian Association for Cancer Research.
- 68% of patients were
- 9.5% of patients had cancer, and 2.6% had prostate cancer.
- Patients with cancer had a higher risk for SARS-CoV-2 infection vs those without:
- OR, 1.79 (95% CI, 1.62-1.98).
- Compared with patients with prostate cancer receiving ADT, the risk for SARS-CoV-2 was significantly higher in:
- Patients with prostate cancer who did not receive ADT: OR, 4.05 (95% CI, 1.55-10.59).
- Patients with any other type of cancer: OR, 5.17 (95% CI, 2.02-13.40).